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Abstract
Background: Although catheter-associated urinary tract infection (CA-UTI) is a major healthcare-related problem
worldwide, there is a scarcity of current data from countries with high antimicrobial resistance rates. We aimed to
determine the clinical outcomes of patients with CA-UTI compared to those of patients with other sources of
complicated urinary tract infection (cUTI), and to assess the impact of antimicrobial resistance. We also aimed to
identify the factors influencing 30-day mortality among patients with CA-UTI.
Methods: This was a multicentre, multinational retrospective cohort study including hospitalised adults with cUTI
between January 2013 and December 2014 in twenty hospitals from eight countries from southern Europe, Turkey and
Israel. The primary endpoint was 30-day mortality. The secondary endpoints were length of hospital stay, symptom
improvement after 7 days’ treatment, symptom recurrence at 30 days and readmission 60 days after hospital discharge.
Results: Of the 807 cUTI episodes, 341 (42.2%) were CA-UTIs. The time from catheter insertion to cUTI diagnosis was
less than 2 weeks in 44.6% of cases. Overall, 74.5% of cases had hospital or healthcare-acquired CA-UTI. Compared to
patients with other cUTI aetiologies, those with CA-UTI had the following characteristics: they were more frequently
males, older, admitted for a reason other than cUTI and admitted from a long-term care facility; had higher Charlson’s
comorbidity index; and more frequently had polymicrobial infections and multidrug-resistant Gram-negative bacteria
(MDR-GNB). Patients with CA-UTI also had significantly higher 30-day mortality rates (15.2% vs 6%) and longer hospital
stay (median 14 [interquartile range -IQR- 7-27] days vs 8 [IQR 5–14] days) than patients with cUTI of other sources.
After adjusting for confounders, CA-UTI was not independently associated with an increased risk of mortality (odds
ratio, 1.40; 95% confidence interval, 0.77–2.54), and neither was the presence of MDR-GNB.
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Conclusions: CA-UTI was the most frequent source of cUTI, affecting mainly frail patients. The mortality of patients
with CA-UTI was high, though this was not directly related to the infection.
Keywords: Catheter-associated urinary tract infection, Antimicrobial resistance, Gram-negative infections
Introduction
Urinary tract infection (UTI) is a major healthcare prob-
lem worldwide. Catheter-associated UTI (CA-UTI) ac-
counts for more than 1 million cases per year in the US
[1]. These infections are also responsible for more than
80% of UTIs originating in the healthcare setting and are
the most frequent cause of both bacteraemia in long-term
care facilities (LTCF) and infection in patients with spinal
cord injury [2, 3]. Approximately 20% of hospitalised pa-
tients have a urinary catheter during admission, with the
risk of CA-UTI increasing by 3–7% per day [4, 5].
Despite efforts to reduce the incidence of CA-UTI, rates
continue to increase, with the US Centres for Disease Control
and Prevention reporting a 6% increase between 2009 and
2013 [6]. The high prevalence of CA-UTI is associated with
significant antimicrobial use, and this not only favours the
emergence and spread of multidrug-resistance (MDR) but
also increases healthcare costs [7–9]. Antibiotic resistance, in
particular, has become a major healthcare problem that com-
plicates treatment and leads to worse outcomes. Even though
these issues exist, CA-UTI is usually seen as a mild or low-
risk infection with no severe consequences for patients. How-
ever, most previous studies seeking to address this issue have
only evaluated specific populations, such as critically ill pa-
tients, which limits extrapolation to other contexts. Thus, the
question of whether CA-UTI development increases the risk
of mortality remains unanswered, not least because conflict-
ing results have previously been reported [10, 11].
We aimed to assess the clinical outcomes of CA-UTI
among hospitalised patients with complicated UTI (cUTI)
in a multicentre study of surgical and medical patients
from eight countries with high prevalence of multidrug-
resistant Gram-negative bacteria (MDR-GNB).
Methods
Study design
The COMBACTE-MAGNET WP5 RESCUING study is
an international, multi-centre, retrospective, observa-
tional cohort study conducted between January 2015
and August 2016. It included both patients diagnosed
with cUTI as the primary reason for hospitalisation and
those who developed cUTI after being hospitalised for
another reason between 1st January 2013 and 31st
December 2014 [12, 13]. The STROBE guidelines for
reporting observational studies were followed [14]. In
the present study, we compared patients who had CA-
UTI with those who had cUTI of other sources.
Setting and patients
The study was conducted at 20 hospitals in Bulgaria,
Greece, Hungary, Israel, Italy, Romania, Spain and
Turkey. Patient selection was done by searching the ap-
propriate Clinical Modification codes at discharge based
on versions 9 or 10 of the International Classification of
Diseases. The sample size was calculated to detect an ab-
solute difference of 10% in the treatment failure rate be-
tween infection due to MDR and other pathogens
(power = 0.83, α = 0.05). We planned to include 50 to 60
patients per hospital to reach a total estimated sample
size of 1000 [15, 16].
The inclusion criteria were based on the Food and
Drug Administration guidance for cUTI [17], requiring
patients to have a UTI plus at least one of the following:
1. At least one from among the following: an indwelling
urinary catheter; urinary retention (at least 100mL of re-
sidual urine after voiding); neurogenic bladder; obstructive
uropathy (e.g., nephrolithiasis or fibrosis); renal impairment
caused by intrinsic renal disease (estimated glomerular fil-
tration rate < 60mL/min); and renal transplantation; urin-
ary tract modification (ileal loop or pouch).
2. At least one from among the following signs or symp-
toms: Chills or rigors associated with fever or hypothermia
(temperature > 38 °C or < 36 °C); flank or pelvic pain, dys-
uria, urinary frequency or urgency; and costovertebral angle
tenderness on physical examination.
3. A urine culture with at least 105 colony-forming
units (CFU)/mL of a uropathogen (no more than two
species); or at least one blood culture growing possible
uropathogens (no more than two species) with no other
evident site of infection.
We excluded patients who were younger than 18 years,
diagnosed with prostatitis (based on Food and Drug Ad-
ministration guidance), diagnosed with pyelonephritis with
normal urinary tract, had polymicrobial infections that in-
cluded Candida spp. or more than two bacterial species, or
who had cUTI with Candida spp. as the sole uropathogen.
Data collection
Data from eligible patients were collected from January
2015 to August 2016. For all patients, a standardised data
set was collected retrospectively from electronic hospital
records and input in a web-based electronic case report
form (eCRF) with controlled access. The data set included
details of demographic characteristics, comorbidities, infec-
tion acquisition site, signs and symptoms, laboratory and
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microbiology test results, and discharge and outcome
details, including death. The follow-up period was limited
to two months after hospital discharge. To ensure data
quality, study sites were monitored and audited.
Definitions
Acquisition of cUTI in a medical care facility was con-
sidered hospital-acquired if it started 48 h or more after
hospital admission. Acquisition of cUTI was considered
healthcare-associated if it was detected at hospital ad-
mission or within the first 48 h of hospitalisation, and
met any of the following criteria: the patient had
received intravenous therapy, wound care or specialist
nursing care at home in the previous 30 days; hospital or
haemodialysis ward attendance or intravenous chemo-
therapy administration in the previous 30 days; hospital-
isation for at least 2 of the previous 90 days; residence in
a long-term care facility; underwent an invasive urinary
procedure in the previous 30 days; or had a long-term
indwelling urethral catheter.
We then defined cUTI as either CA-UTI or cUTI of
other source (other-cUTI). The CA-UTI group comprised
those with UTI related to indwelling urinary catheterisa-
tion, including long-term, short-term or intermittent cath-
eterisation. The other-cUTI group included those with all
other causes of cUTI, including the following: UTI related
to anatomical urinary tract modification (including any
urinary diversion procedure, nephrostomy, stent or renal
transplant); UTI related to obstructive uropathy (including
any obstruction intrinsic or extrinsic to the urinary tract,
such as lithiasis, tumour, ureteral herniation or prostate
hyperplasia); UTI related to events that do not fall under
any other category (such as neurogenic bladder).
MDR was defined in accordance with the international
expert proposals of Magiorakos et al., as non-susceptibility
to at least one agent in three or more antimicrobial cat-
egories (extended-spectrum penicillins, carbapenems,
cephalosporins, aminoglycosides and fluoroquinolones)
[18]. Extensive drug-resistance (XDR) was defined as
non-susceptibility to at least one agent in all but two or
fewer antimicrobial categories.
Steroid therapy was defined as the administration of a
dose of at least 10 mg of prednisolone or an equivalent
dose of another steroid for 30 days or more prior to the
diagnosis of cUTI.
Length of hospital stay was considered in all cases
from the day of diagnosis of cUTI to the day of dis-
charge or mortality.
Clinical outcomes
The primary endpoint was 30-day mortality. The second-
ary endpoints were length of hospital stay, symptom im-
provement at 7 days of treatment, symptom recurrence at
30 days from diagnosis, and readmission rate at 60 days
from discharge. We also aimed to identify the factors in-
fluencing 30-day mortality among patients with CA-UTI.
Statistical methods
Demographic, clinical and outcome data for patients in
the CA-UTI and other-cUTI groups were described
using appropriate statistics according to the nature and
distribution of the variable. The statistical analyses were
performed using version 3.5.0 of R for Windows. Statis-
tical significance was set at a probability level of < 0.05.
The crude and adjusted association between the pres-
ence of CA-UTI and the 30-day mortality was analysed
by logistic modelling with mixed-effects that took into
account the variability between centres. The patient
demographics and variables associated with 30-day mor-
tality by unadjusted analysis (Charlson index, having
haematological malignancy, basal functional status, place
of cUTI acquisition and reason for admission) were used
for adjustment. Although these adjustment variables
were initially chosen on clinical grounds, they were re-
quired to modify the coefficient of the main variable
(CA-UTI) by more than 10 to remain in the model. The
impact of the assessment centre was evaluated by the
intra-class correlation (ICC), which measures how much
of the overall variation in the outcome is explained
simply by clustering. ICC ranges from 0 to 1; a value
close to 1 indicates that patients within centers are more
similar than patients between centers, and a value close
to 0 indicates that patients between centers are similar.
Residues were validated graphically, and the conditions
of application of the models were tested. The odds ratios




Table 1 shows the baseline characteristics of patients in
the CA-UTI and other-cUTI groups. In total, 807 epi-
sodes of cUTI were included, of which 341 (42.2%) had
CA-UTIs. The time between catheter insertion and diag-
nosis was < 2 weeks in 44.6%. The CA-UTI was hospital-
acquired in 130 (38.1%), healthcare-acquired in 124
(36.4%) and community-acquired in 87 (25.5%) cases.
Among those with hospital-acquired disease, 50 (38.4%)
cases had onsets in ICU. Compared with the other-cUTI
group, the CA-UTI group were more frequently male,
older, admitted for a reason other than cUTI, and
acquired the infection in a medical care facility. The
Charlson score was also higher in the CA-UTI group.
Causative agents
Table 2 shows the most frequent aetiologies of cUTI.
Compared with the other-cUTI group, the CA-UTI
group more frequently had polymicrobial infection
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(21.1% vs 10.1%, p < 0.001), infections caused by Pseudo-
monas aeruginosa (16.7% vs 7.7%, p < 0.001), Proteus
mirabilis (11.7% vs 5.6%, p < 0.001) or Enterococcus spp.
(11.1% vs 6.4%, p = 0.017). There was also a higher fre-
quency of MDR-GNB in the CA-UTI group compared
with the other-cUTI group (35.2% vs 23%, p < 0.001).
The MDR-GNB resistance profiles in patients with CA-
UTI are shown in the Additional file 1.
Clinical outcomes
Primary outcome
The 30-day mortality in the CA-UTI group was signifi-
cantly higher than that in the other-cUTI group (52/341
[15.2%] vs 28/466 [6%], p < 0.001). Table 3 shows the
crude association between patient characteristics and
30-day mortality considering the hospital effect in the
entire cohort. Even though ICC values are not far from
0, values above 0.20 suggest that patients’ characteristics
within centers are more similar than patients’ character-
istics between centers. The unadjusted OR of CA-UTI






Male gender, n (%) 197 (57.8%) 222 (47.6) 0.006
Age, median (IQR) 71 (60–82) 68 (56.2–79) 0.009
Diabetes mellitus, n (%) 109 (32.2) 113 (24.2) 0.019
Haematological malignancy, n (%) 8 (2.3) 10 (2.1) 0.84
Solid tumour, n (%) 42 (12.3) 63 (13.8) 0.74
Liver disease, n (%) 16 (4.7) 26 (5.58) 0.68
Urgent admission, n (%) 285 (83.6) 394 (84.5) 0.78
Admission reason: < 0.001
Other reasons 213 (62.5) 120 (25.8)
cUTI 128 (37.5) 346 (74.2)
Admission from medical care facility, n (%) 88 (25.8) 90 (13.5) < 0.001
Charlson score, median (IQR) 3 (1–5) 2 (0–4) < 0.001
Organ transplantation, n (%) 10 (2.9) 50 (10.7) < 0.001
Immunosuppressive therapy, n (%) 19 (5.6) 63 (13.5) < 0.001
Steroid therapy, n (%) 22 (6.5) 32 (6.87) 0.92
Functional capacity: Bedridden, n (%) 91 (26.7) 55 (11.8) < 0.001
Chronic renal impairment, n (%) 72 (21.2) 141 (30.8) 0.005
UTI within 1 year, n (%) 79 (23.2) 143 (30.8) 0.021
Antibiotic within 30 days, n (%) 67 (19.7) 104 (22.5) 0.39
Acquisition of cUTI at a medical care facility, n (%) 254 (74.5) 160 (34.3) < 0.001
Urinary retention, n (%) 70 (20.5) 112 (24) 0.27
Neurogenic bladder 32 (9.4) 12 (2.58) < 0.001
Obstructive uropathy 43 (12.6) 166 (35.8) < 0.001
Severity of infection: Severe sepsis/septic shock, n (%) 49 (15.4) 70 (15.9) 0.92
CA-UTI catheter-associated urinary tract infection (CA-UTI), complicated urinary tract infection due to other sources (other-cUTI). IQR Interquartile range, cUTI
complicated urinary tract infection, and UTI urinary tract infection






Bacteraemia, n (%) 62 (18.2) 67 (14.4) 0.14
Polymicrobial infection, n (%) 72 (21.1) 47 (10.1) < 0.001
Escherichia coli, n (%) 127 (37.2) 287 (61.6) < 0.001
Klebsiella pneumoniae, n (%) 63 (18.5) 80 (17.2) 0.63
Pseudomonas aeruginosa, n (%) 57 (16.7) 36 (7.7) < 0.001
Proteus mirabilis, n (%) 40 (11.7) 26 (5.6) 0.002
Acinetobacter baumannii, n (%) 22 (6.5) 3 (0.6) < 0.001
MDR-GNB, n (%) 120 (35.2) 107 (23) < 0.001
Enterococcus, n (%) 38 (11.1) 30 (6.4) 0.017
Staphylococcus aureus, n (%) 6 (1.8) 4 (0.9) 0.25
Other microorganisms, n (%) 55 (16.1) 45 (9.7) 0.006
CA-UTI catheter-associated urinary tract infection, complicated urinary tract
infection due to other sources (other-cUTI), and MDR-GNB multidrug-resistant
Gram-negative bacteria
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for 30-day mortality was 2.56 (95% CI 1.52–4.32). Table 4
shows the adjusted models of mortality first in the entire
cohort (Model 1), secondly in the subgroup of patients
admitted for cUTI (Model 2) and thirdly in patients
admitted for other conditions than cUTI but who
developed cUTI during hospitalisation (Model 3). To
evaluate the effect of CA-UTI on 30-day mortality, the
factor presence of severe sepsis or septic shock (un-
adjusted OR 11.7) was not included in the models
because its strong association precluded the evaluation
of any other effects. After adjustment, in none of the
three models the CA-UTI remained as independent pre-
dictor of 30-day mortality (OR 1.40; 95%CI 0.77–2.54 in
Model 1, OR 1.62; 95% CI 0.63–4.15 in Model 2 and OR
1.24; 95% CI 0.54–2.81 in Model 3).
Microbiology, including the presence of MDR-GNB,
had no effect on 30-day mortality. The sub-analysis of 668
cases in which we could assess the adequacy of empiric
antibiotic treatment failed to show that this variable af-
fected the 30-day mortality (Additional file 1). The factors
predictive of 30-day mortality in patients with CA-UTI in
the entire cohort were as follows: male gender (OR 0.53;
95% CI 0.31–0.90) as protective factor and age (OR per
year 1.57; 95% CI 1.12–2.19), having a haematological
malignancy (OR 6.08; 95% CI 1.84–20.07), Charlson index
(OR 1.45 per point; 95% CI 1.12–1.88), being bedridden
Table 3 Crude association between the baseline characteristics of patients with cUTI and the 30-day mortality
Variable OR 95% CI p-value ICCa
Male gender 0.62 0.39–1.01 0.07 0.2039
Age 1.03 1.01–1.05 0.001 0.1871
Diabetes mellitus 0.98 0.58–1.66 0.82 0.1989
Haematological malignancy 6.02 2.11–17.23 < 0.001 0.1918
Solid tumour 1.5 0.78–2.89 0.36 0.2035
Liver disease 1.39 0.5–3.83 0.65 0.2002
Charlson index 1.21 1.11–1.33 0.001 0.1723
Organ transplant 0.61 0.2–1.87 0.08 0.1965
Immunosuppressive therapy 0.7 0.28–1.74 0.40 0.1962
Corticosteroid therapy 1.09 0.45–2.65 0.21 0.1964
Bedridden functional capacity 3.13 1.83–5.37 < 0.001 0.1683
Chronic renal impairment 1.16 0.67–2.03 0.23 0.1817
UTI within 1 year 0.77 0.42–1.41 0.11 0.1878
Antibiotic within 30 days 0.63 0.32–1.23 0.09 0.1869
Acquisition of cUTI in a medical care facility 2.42 1.41–4.15 0.001 0.1677
Urinary retention 0.75 0.39–1.44 0.78 0.2149
Neurogenic bladder 1.51 0.6–3.79 0.39 0.2001
Obstructive uropathy 0.46 0.23–0.91 0.05 0.1905
Severe sepsis/ septic shock 11.7 6.18–22.14 < 0.001 0.3077
Polymicrobial infection 1.16 0.63–2.15 0.28 0.1947
MDR-GNB 1.13 0.66–1.93 0.69 0.1887
Urgent admission 1.15 0.55–2.39 0.92 0.2006
Admission reason: UTI 0.28 0.16–0.5 < 0.001 0.1683
Admission from a medical care facility 2.49 1.47–4.19 0.001 0.2014
Escherichia coli 0.67 0.42–1.1 0.09 0.1946
Klebsiella pneumoniae 1.05 0.56–1.96 0.95 0.1989
Pseudomonas aeruginosa 0.7 0.31–1.58 0.41 0.1998
Enterococcus 0.9 0.38–2.15 0.91 0.1999
Proteus mirabilis 1.58 0.75–3.32 0.13 0.1947
Urinary catheter as infection source 2.56 1.52–4.32 < 0.001 0.1471
OR odds ratio, 95%CI 95% confidence interval, ICC intra-class correlation, UTI urinary tract infection, cUTI complicated urinary tract, and MDR-GNB Multidrug-
resistant Gram-negative bacteria
aThe ICC (range 0 to 1) expresses the magnitude of clustering. A high ICC (generally higher than 0.1) means that individuals within centers are more similar than
between centers
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(OR 2.48; 95% CI 1.39–4.43) and being admitted for other
condition than UTI (OR 2.70; 95% CI 01.40–5.00) as
risk factors. In the subgroup of patients admitted for
UTI only male gender and being bedridden were in-
dependent predictors of mortality, while in the sub-
group of patients admitted for other conditions than
UTI predictive factors were age, having a haemato-
logical malignancy, Charlson score and being func-
tionally bedridden.
Secondary outcomes
Patients with CA-UTI had prolonged overall length of
hospital stay (median 14 [IQR 7–27] days vs 8 [IQR 5–
14] days, p < 0.001) than patients with other cUTI,
nevertheless, when stratifying by admission reason this
increment was at the expense of the subgroup of
patients admitted due to other conditions than UTI (me-
dian 20 [IQR 12–30] days in CA-UTI vs 12 [IQR 8–21]
days in other cUTI, p < 0.001). The subgroup of patients
admitted for UTI showed similar length of stay regard-
less of the source of UTI (CA-UTI vs others), as shown
in Table 5. There were no differences in other outcome
variables between groups.
Discussion
In this multicentre, multinational, retrospective cohort
study we observed that CA-UTI was the most frequent
source of cUTI, typically involving older males with more
comorbidities and MDR-GNB. The 30-day mortality of
the CA-UTI group was higher than that of the other-cUTI
group, but after adjusting for confounders, CA-UTI was
not independently associated with 30-day mortality.
The present study included a large and recent cohort
of patients with cUTI. The profile of patients with CA-
UTI is consistent with that reported in previous studies
[2, 19], with these patients frequently having polymicro-
bial infections and MDR-GNB other than E. coli [20].
The repeated antibiotic courses and the healthcare
Table 4 Adjusted logistic mixed-effects models of predictive factors for 30-day mortality
Model 1 Model 2 Model 3
All cohort Admitted for UTI Admitted for other condition
OR 95% CI p OR 95% CI p OR 95% CI p
Fixed parts
(Intercept) 0.08 0.04–0.16 < 0.001 0.02 0.01–0.08 < 0.001 0.07 0.03–0.18 < 0.001
CA-UTI 1.40 0.77–2.54 0.269 1.62 0.63–4.15 0.314 1.24 0.54–2.81 0.610
Male gender 0.53 0.31–0.90 0.019 0.31 0.12–0.80 0.016 0.77 0.40–1.51 0.450
Age 1.57 1.12–2.19 0.009 1.69 0.93–3.05 0.084 1.57 1.03–2.39 0.036
Haematologic malignancy 6.08 1.84–20.07 0.003 2.33 0.19–29.45 0.512 14.82 2.83–77.61 0.001
Charlson score 1.45 1.12–1.88 0.005 1.28 0.83–1.96 0.257 1.64 1.16–2.33 0.005
Bedridden functional capacity 2.48 1.39–4.43 0.002 3.10 1.13–8.50 0.028 2.00 0.94–4.28 0.073
Acquisition in a medical care facility 1.73 0.93–3.23 0.085 1.58 0.63–3.95 0.327 1.71 0.69–4.25 0.247
Admission reason: other condition than UTI 2.70 1.40–5.00 0.003
Random effects
τ00 0.37 0.96 0.24
ICC 0.1 0.23 0.09
Observations 807 474 333
Marginal R2/Conditional R2 0.278/0.350 0.210/0.389 0.223/0.292
UTI urinary tract infection, OR odds ratio, 95%CI 95% confidence interval, CA-UTI catheter-associated urinary tract infection, ICC intra-class correlation






LOS of patients admitted for UTI (n = 474)a 8 (5–19) 7 (5–12) 0.226
LOS of patients admitted for other condition (n = 333)a 20 (12–30) 12 (8–21) < 0.001
Improvement of symptoms at 5–7 days of treatment, n (%) 238 (70) 343 (73.6) 0.26
Recurrence of symptoms at 30 days, n (%) 28 (8.3) 42 (9.1) 0.69
Readmission at 60 days of discharge, n (%) 56 (16.4) 91 (19.5) 0.25
CA-UTI catheter-associated urinary tract infection, LOS length of stay, cUTI complicated urinary tract infection, IQR interquartile range
aLength of stay calculated from diagnosis of cUTI to discharge from hospital
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environment to which these patients are exposed both
increase the risk of acquiring MDR-GNB strains.
Our CA-UTI group had higher 30-day mortality rates
than our other-cUTI group. However, the adjusted models
of mortality in the entire cohort and in the subgroups of
patients according to admission reason accounting for
variation between hospitals and confounding factors did
not show an association between 30-day mortality and
presence of CA-UTI. Nevertheless, OR of CA-UTI in pa-
tients admitted for other condition than UTI was lower
than of patients admitted due to UTI, indicating that in
the latter group comorbidities had the greatest impact on
mortality. The presence of MDR-GNB or adequate empir-
ical antibiotic treatment did not influence mortality in pa-
tients with CA-UTI. It should be noted that patients with
severe sepsis or septic shock were excluded from these
analyses because this factor strongly affects mortality and
would have precluded evaluation of the effect of CA-UTI.
The relationship between CA-UTI and mortality risk
in previous studies varies significantly. One study of
trauma patients admitted to a single institution showed
a significant association between mortality and CA-UTI,
although this was mostly observed to be associated with
increasing age [11]. Another study involving patients
following cardiac surgery showed 30-day mortalities of
10.9 and 3.2% in patients who developed CA-UTIs or
other cUTIs, but none of these deaths were directly at-
tributed to the cUTI. Multivariate analysis discarded an
association between developing a CA-UTI and mortality.
Nonetheless, the authors argued that efforts to reduce
CA-UTI would be worthwhile in this population by im-
proving their management. Similar results were found in
a study in which patients with CA-UTI in intensive care
unit and general ward settings both had significantly
higher mortality than those without CA-UTI; but, these
results did not remain significant after adjustment [10].
Chant et al. [21] performed a meta-analysis of 11 ob-
servational case-control studies assessing the risk of
mortality associated with CA-UTI among critically ill pa-
tients. They found no association between CA-UTI and
30-day mortality after adjusting for confounders, but did
find an association between CA-UTI and length of stay,
which was increased. We observed longer stays after
UTI diagnosis among patients with CA-UTI than among
patients without CA-UTI, mainly at the expense of those
admitted for other condition than UTI. It’s probable that
the greater comorbidities in these patients lead to a
more protracted clinical course of UTI.
As previously reported, we showed that administering
adequate empiric antibiotic treatment to patients with
CA-UTI made no difference to outcomes. When we also
consider the role of MDR-GNB in this population, it has
been suggested that treatment should be delayed until
the results of sensitivity tests are available [22]. However,
empiric treatment should still be initiated as soon as
possible to avoid adverse outcomes in patients present-
ing with severe sepsis or septic shock.
The present study has a number of limitations that
should be acknowledged. Notably, as with any retro-
spective observational study, there is a potential for re-
sidual confounding from factors that can influence 30-
day mortality but that were not evaluated. Nevertheless,
our results are reinforced by the large-scale multi-centre
design and the fact that we considered possible differ-
ences in outcomes between hospitals. By including pa-
tients with different characteristics and from different
countries increases the generalisability of our data. In
addition, the presence of competing events that could
modify outcomes was ruled out.
Conclusions
Patients with CA-UTI tend to be older and to have greater
morbidity and mortality than patients with cUTI of other
sources. Despite this, the 30-day mortality does not appear
to be directly related to the presence of CA-UTI.
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